Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $30.00 at Chardan Capital

Intellia Therapeutics (NASDAQ:NTLA) had its price target increased by Chardan Capital from $27.00 to $30.00 in a research report report published on Monday, Marketbeat.com reports. Chardan Capital currently has a buy rating on the stock.

Several other equities research analysts also recently weighed in on the company. Wells Fargo & Company increased their price target on Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 3rd. Truist Financial raised Intellia Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Tuesday, April 21st. Royal Bank Of Canada increased their price target on Intellia Therapeutics from $9.00 to $15.00 and gave the stock a “sector perform” rating in a research report on Tuesday, March 3rd. Finally, Robert W. Baird set a $7.00 price target on Intellia Therapeutics in a research report on Tuesday, January 27th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $20.05.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $13.01 on Monday. The business’s 50-day moving average is $13.59 and its two-hundred day moving average is $12.89. The company has a market capitalization of $1.54 billion, a P/E ratio of -3.40 and a beta of 1.99. Intellia Therapeutics has a fifty-two week low of $6.83 and a fifty-two week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.16. The company had revenue of $23.02 million for the quarter, compared to the consensus estimate of $12.17 million. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The firm’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same period last year, the firm earned ($1.27) EPS. Analysts forecast that Intellia Therapeutics will post -3.53 EPS for the current year.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors have recently modified their holdings of NTLA. Contrarius Group Holdings Ltd grew its position in shares of Intellia Therapeutics by 279.4% during the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after acquiring an additional 4,337,428 shares during the period. ARK Investment Management LLC grew its position in shares of Intellia Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after acquiring an additional 2,288,146 shares during the period. Vanguard Group Inc. grew its position in shares of Intellia Therapeutics by 17.8% during the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after acquiring an additional 1,965,181 shares during the period. State Street Corp grew its position in shares of Intellia Therapeutics by 29.1% during the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after acquiring an additional 1,447,967 shares during the period. Finally, Jupiter Asset Management Ltd. acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at about $23,519,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

More Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Intellia reported positive topline Phase 3 HAELO results for lonvoguran (ziclumeran) that met the primary and all key secondary endpoints and showed favorable safety — a potential first-ever one-time in‑vivo gene‑editing therapy for HAE, a major clinical milestone. Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema
• Positive Sentiment: Intellia initiated a rolling BLA submission to the FDA for lonvo‑z and provided a first‑half‑2027 U.S. launch expectation if approved — a clear path to commercialization that materially derisks program timing. Intellia Initiates Rolling Submission of BLA to FDA for Lonvoguran
• Positive Sentiment: Major media and wire coverage (Reuters, CNBC) highlighted the Phase 3 success as a landmark for in‑vivo CRISPR therapy, boosting investor interest and helping premarket rallies. Reuters: Intellia therapy meets main goal in trial
• Positive Sentiment: Analyst support and call buying: Chardan raised its price target to $30 (buy) and there was unusual call activity (nearly double typical call volume), signaling bullish speculation around the program. Benzinga / The Fly: Price target and options
• Neutral Sentiment: Robert W. Baird raised its target to $13 and kept a neutral rating — this is a mild endorsement but less bullish than Chardan’s view, reflecting some investor caution on commercialization and valuation. Benzinga: Baird raises target
• Neutral Sentiment: Coverage pieces noting “why shares aren’t flying” provide context: investors are weighing one‑time curative potential against commercial, regulatory and manufacturing unknowns — explains a muted or mixed price response despite big clinical news. MSN: Why shares aren’t flying
• Negative Sentiment: Intellia announced a $150M underwritten public offering (plus a 15% overallotment option). New share issuance is dilutive and often puts short‑term pressure on the stock despite positive clinical news. GlobeNewswire: Proposed public offering
• Negative Sentiment: Despite the favorable trial, several outlets reported intraday selling/stock declines — likely profit‑taking, dilution worries from the offering, and investors locking gains after a big premarket pop. Investing.com: Stock falls despite positive results

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.